Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6

Benzinga · 2d ago
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.